Chapter 5.1

Identification of copy number variants associated with BPES-like phenotypes

Antoinet CJ Gijsbers¹, Barbara D’haene², Yvonne Hilhorst-Hofstee¹, Marcel Mannens³, Beate Albrecht⁴, Joerg Seidel⁵, David R Witt⁶, Melissa K Maisenbacher⁷, Bart Loeys², Ton van Essen⁸, Egbert Bakker¹, Raoul Hennekam⁹, Martijn H Breuning¹, Elfride De Baere² and Claudia AL Ruivenkamp¹

1) Center for Human and Clinical Genetics; Leiden University Medical Center (LUMC), The Netherlands
2) Center for Medical Genetics; Ghent University Hospital, Belgium
3) Center for Clinical Genetics; Amsterdam Medical Center (AMC), The Netherlands
4) Institut fur Humangenetik; Universitaetsklinikum Essen, Germany
5) Department of Pediatrics; SRH -Klinikum Gera, Germany
6) Genetics Department; Kaiser Permanente, San Jose, CA, USA
7) Division of Genetics, Department of Pediatrics; University of Florida, Gainesville, FL, USA
8) Department of Genetics; University Medical Center Groningen; University of Groningen, The Netherlands
9) Department of Paediatrics, Amsterdam Medical Center (AMC), The Netherlands and Institute of Child Health, Great Ormond Street Hospital for Children, UCL, London, England

Hum Genet 2008;124:489-498
Abstract
Blepharophimosis-Ptosis-Epicanthus inversus Syndrome (BPES) is a well characterized rare syndrome that includes an eyelid malformation associated with (type I) or without premature ovarian failure (type II). Patients with typical BPES have four major characteristics: blepharophimosis, ptosis, epicanthus inversus and telecanthus. Mutations in the \textit{FOXL2} gene, encoding a forkhead transcription factor, are responsible for the majority of both types of BPES. However, many patients with BPES-like features, i.e. having at least 2 major characteristics of BPES, have an unidentified cause. Here, we report on a group of 27 patients with BPES-like features, but without an identified genetic defect in the \textit{FOXL2} gene or flanking region. These patients were analyzed with whole-genome high-density arrays in order to identify copy number variants (CNVs) that might explain the BPES-like phenotype. In 9 out of 27 patients (33%) CNVs not previously described as polymorphisms were detected. Four of these patients displayed psychomotor retardation as an additional clinical characteristic. In conclusion, we demonstrate that BPES-like phenotypes are frequently caused by CNVs, and we emphasize the importance of whole-genome copy number screening to identify the underlying genetic causes of these phenotypes.

Introduction
Blepharophimosis and ptosis are a reduction in the horizontal and vertical dimensions of the palpebral fissures respectively (Guercio et al. 2007). From the 135 syndromes in the London Dysmorphology Database with blepharophimosis and ptosis, 6 are known to be associated with a chromosomal microdeletion (Winter et al. 2008). In addition, a recent literature review illustrates that chromosomal aberrations are probably the most important underlying cause in patients with blepharophimosis and mental retardation phenotypes (Bartholdi et al. 2008). Only a few blepharophimosis syndromes have known causative genes: the Schwartz-Jampel syndrome (OMIM 255800), Freeman Sheldon syndrome (OMIM 193700), Hereditary neuralgic amyotrophy syndrome (HNA; OMIM 162100) (Laccone et al, 2008) and Blepharophimosis-Ptosis-Epicanthus inversus syndrome (BPES) (OMIM 110100). BPES is a rare autosomal dominant disorder characterized by a dysplasia of the eyelids. There are two types of clinical presentation: type I is associated with premature ovarian failure, whereas type II has no associated symptoms (Zlotogora et al. 1983). The typical BPES phenotype is characterized by four major features blepharophimosis, ptosis, epicanthus inversus (a small skin fold which arises from the lower eyelid and runs inwards and upwards) and telecanthus (increased distance between the medial lid margins). Haploinsufficiency of the \textit{FOXL2} gene, encoding a putative forkhead transcription factor located at chromosome 3q23, is responsible for both types of BPES (Crisponi et al. 2001; De Baere et al. 2001; De Baere et al. 2003). Using a combined mutation detection approach, it is possible to reveal the causal genetic defect in 88% of typical BPES patients. Molecular defects include chromosomal rearrangements (2%), intragenic mutations (81%) and genomic rearrangements comprising both deletions encompassing \textit{FOXL2} (12%) and deletions located outside its transcription unit (5%) (Beysen et al. 2005; Beysen et al. 2008). The lack of a detectable genetic \textit{FOXL2} defect might be explained by several grounds, including subtle extragenic rearrangements, epigenetic changes and referral bias by the different clinicians (Beysen et al. 2008). Here, we focus on series of 27 patients with BPES-like features (i.e. having at least two main characteristics of typical BPES), who tested negative for \textit{FOXL2} mutations and deletions of the \textit{FOXL2} region, and in whom
the causal defect remains to be elucidated (Beysen et al. 2008). Novel whole-genome array-based technologies can detect copy number variants (CNVs) at much higher resolution than conventional cytogenetic methods, and hence might reveal CNVs that were previously unidentified. These techniques have been used with considerable success to reveal de novo CNVs in several phenotypes, including mental retardation and dysmorphism (Stankiewicz and Beaudet 2007; Slavotinek 2008). Yet, the association between CNVs and BPES-like phenotypes has not been investigated. We performed whole-genome high-density arrays in the group of 27 FOXL2 mutation-negative patients with a BPES-like phenotype in order to identify the underlying genetic cause explaining the phenotypes.

**Methods**

**Patients**

Genomic DNA was obtained from 27 patients with a BPES-like phenotype, being patients for whom at least two of the four diagnostic criteria of BPES (i.e. blepharophimosis, ptosis, epicanthus inversus and telecanthus), were mentioned on a clinical questionnaire. In 11 of the patients psychomotor retardation was identified as an additional clinical feature. Furthermore, all patients were clinically assessed by different clinicians. The patients were recruited in three genetic centers: (1) 22 patients from the Center for Medical Genetics, Ghent University Hospital, Belgium. Genomic patient DNA was used that was available from previously approved mutation studies (De Baere et al. 2001; De Beare et al. 2003; Beysen et al. 2005; Beysen et al. 2008); (2) 3 families from the Department of Clinical Genetics, Amsterdam Medical Centre, The Netherlands; (3) 2 patients from the Department of Clinical Genetics, Leiden University Medical Center, The Netherlands.

All patients were initially referred for FOXL2 screening. Intragenic FOXL2 mutations and copy number variants of the FOXL2 gene and surrounding region were excluded in all patients by sequencing of the coding region and multiplex ligation-dependent probe amplification (MLPA) (P054, MRC Holland). In addition, conventional karyotyping was performed in 13 patients and considered normal.

**Single Nucleotide Polymorphism arrays**

Affymetrix GeneChip Human Mapping 262K NspI. This array was used for one patient and his parents. This SNP array contains ~262,000 25-mer oligonucleotides with an average spatial resolution of ~12 kb. An amount of 250 ng DNA was processed according to the manufacturer’s instruction (http://www.affymetrix.com). SNP copy number was assessed in the patient using DNA-Chip Analyzer (dChip) software (version release 02-16-06) (Li and Wong, 2001).

Illumina’s Sentrix HumanHap300 Genotyping Beadchip. This platform was used for 23 patients. This array contains ~317,000 TagSNPs with a mean spatial resolution of approximately 9 kb. A total of 750 ng DNA was processed according to the manufacturer’s instruction (http://www.illumina.com). SNP copy number (logRratio) and B allele frequency were assessed in the patients using BeadStudio Version 3.2 (Illumina, Inc.).

Illumina’s HumanCNV370-Duo BeadChip. For three patients this platform was used. This array contains ~317,000 TagSNPs and 52,000 non-polymorphic markers to specifically
target nearly 14,000 known copy number variants with a mean spatial resolution of approximately 7.7 kb. The experiment was performed as described above. SNP copy number and B allele frequency were assessed in BeadStudio, Version 3.2 (Illumina, Inc.).

Evaluation of CNVs
Based on in-house validation studies deletions of at least 5 adjacent SNPs or with a minimum size of 150 kb and duplications of at least 7 adjacent SNPs or with a minimum size of 200 kb were considered significant. All CNVs identified in this study were assessed by screening them against the Database of Genomic Variants (DGV) (http://projects.tcag.ca/variation/) and against our in-house available reference set of approximately 1000 individuals. All regions that significantly overlapped with known polymorphic CNVs were excluded from further research.

MLPA
MLPA experiments were carried out to validate the presence of deletions and duplications identified by the arrays. When an aberration was confirmed by MLPA, the same probe set was used to perform segregation analysis in the parents (if available). At least two synthetic MLPA probes were designed within the aberration and MLPA experiments were performed as described (White et al. 2004). Probes were commercially obtained from Biolegio (Malden, The Netherlands). Amplification products were identified and quantified by capillary electrophoresis on an ABI 3130 genetic analyzer (Applied Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). Fragment analysis was performed with the GeneMarker Software V1.51 (SoftGenetics, USA). Thresholds for deletions and duplications were set at 0.75 and 1.25 respectively (White et al. 2004).

Fluorescent In Situ Hybridisation Analysis (FISH)
FISH analysis was carried out by standard procedures as described (Dauwerse et al. 1990). FISH analysis was performed to verify the imbalances found with the array experiments and to exclude more complex rearrangements. BAC clones mapping to the unbalanced chromosome regions were selected based on their physical location within the affected region (http://www.ensembl.org: Ensembl release 48 - dec 2007).

Gene prioritisation
The software tool Anni 2.0 (http://www.biosemantics.org/Anni) was used to search for potential candidate genes for BPES-like features in the CNVs found. For each gene a profile of related concepts is constructed that summarizes the context in which the gene is mentioned in the literature. Genes associated with similar topics are identified by hierarchical clustering of the corresponding gene concept profiles. The software was used according to the software’s manual (Jelier et al. 2007).

Results and discussion
Identification and confirmation of 12 significant CNVs
In this study we included 27 patients based on the following criteria: (1) BPES-like phenotype (i.e. 2 or more major features of BPES, with or without additional dysmorphic features and psychomotor retardation); (2) exclusion of a FOXL2 mutation or deletion of the FOXL2 region. These patients were analyzed with whole-genome high-density arrays with an average spatial resolution of approximately 10 kb, in
SNP array analysis in patients with a BPES-like phenotype

We identified 12 CNVs not previously described in phenotypically normal individuals according to the DGV and our in-house reference set, in 9 out of 27 patients (33%). An overview of these changes is provided in Table 5.1.1. We found 6 duplications and 6 deletions. In 3 patients (cases 7, 8 and 9) a deletion as well as a duplication was identified, suggesting the presence of an unbalanced translocation. The identified CNVs vary in size from 485 kb to 21.9 Mb. Table 5.1.2 represents the available clinical features from 8 out of the 9 patients carrying chromosome imbalances. Four of these patients display psychomotor retardation as an additional clinical feature.

Each of the 12 CNVs was confirmed by a second independent technique, either MLPA (patients 1-3, 5, 7-8), FISH (patients 4, 9) or another SNP array platform (patient 6). In 8 of 9 cases parental DNA was available for segregation analysis. MLPA and FISH analysis in these cases determined that chromosomal aberrations arose de novo in 5 out of 8 individuals (patients 1-4, 8).

De novo single CNVs

The CNVs identified in cases 1 and 2 were recently described in patients with BPES-like features, developmental delay and other dysmorphic features (Schinzel et al. 1991; Tinkle et al. 2003; Shaw-Smith et al. 2006; Koolen et al. 2006; Koolen et al 2008).

Patient 1 had an interstitial deletion of 18q12.2q21.1 (14.3 Mb), and displayed blepharophimosis, ptosis, epicanthus inversus, and mild dysmorphic features (abnormal nose and ears). The patient died at the age of 4. Several cases have been described with del(18)(q12.2q21.1) showing a consistent clinical pattern of mild dysmorphic features, blepharophimosis, obesity, mental retardation, seizures, behavioral problems, and lack of major congenital anomalies (Schinzel et al. 1991; Tinkle et al. 2003).

In patient 2 an interstitial microdeletion of 17q21.31 (485 kb) was found (Fig. 5.1.1), overlapping with the region that was recently described in the new microdeletion syndrome 17q21.31 (Shaw-Smith et al. 2006; Koolen et al 2008). This new microdeletion syndrome was originally identified by high-resolution genome analyses in patients with unexplained mental retardation, and was recently further characterized clinically and molecularly (Koolen et al. 2008). The deletions are associated with a common inversion polymorphism. Individuals carrying this deletion display a recognizable phenotype of blepharophimosis, a characteristic long face with pear shaped nose, large ears, hypotonia and mental retardation. Interestingly, the phenotype of patient 2, characterized by blepharophimosis, bilateral ptosis, epicanthus inversus, telecanthus, broad pear shaped nose, large ears, central and peripheral hypotonia, and psychomotor retardation, is in agreement with this recognizable 17q21.31 microdeletion syndrome.

Patient 3 had a small interstitial duplication of 16p13.3 (1.1 Mb). To our knowledge, two patients have been reported with a partially overlapping duplication of this region, including a patient with an interstitial duplication of 345 kb - 480 kb on 16p13.3, encompassing the TRAP1 and CREBBP genes that are also duplicated in patient 3 (Thienpont et al. 2007). The second patient was reported to have a duplication of 16p13.3 with a minimal and maximal size of 4.5 Mb and 7 Mb respectively (de Ravel et al. 2005). The duplicated region of patient 3 overlaps over at least 620 kb with the reported duplications. However, the two reported patients display no BPES-like features, suggesting that the region of approximately 600 kb that does not overlap is...
| ID | Gain/ Loss | Chromosome | Starting probe | Ending probe | Size of CNV | Array | Confirmation | Status of inheritance | Number of genes |
|----|------------|------------|----------------|--------------|-------------|-------|--------------|----------------------|----------------|
| 1  | Loss       | 18q12.2q21.1 | rs1693336      | rs2576050    | 14.3 Mb     | II    | MLPA        | de novo              | 18             |
| 2  | Loss       | 17q21.31q21.31 | rs393152       | rs2016730    | 485 kb      | II    | MLPA        | de novo              | 3              |
| 3  | Gain       | 16p13.3p13.3 | rs11077336     | rs2239316    | 1.1 Mb      | II    | MLPA        | de novo              | 21             |
| 4  | Loss       | 10p12.33p12.31 | rs17140331     | rs11012683   | 4.5 Mb      | I     | FISH        | de novo              | 7              |
| 5  | Gain       | 11p15.4p15.4 | rs7117223      | rs4237772    | 545 kb      | II    | MLPA        | maternal             | 5              |
| 6  | Gain       | 9q34.1q34.2  | rs3012755      | rs2027963    | 1.4 Mb      | II    | I           | maternal             | 23             |
| 7  | Loss       | 10q25.2      | rs10885243     | rs9630042    | 21.9 Mb     | II    | MLPA        | n/a                  | 61             |
| 8  | Gain       | 11q24.3      | rs1940363      | rs4508216    | 5 Mb        | II    | MLPA        | n/a                  | 18             |
| 9  | Loss       | 3p25.3       | rs9681213      | rs3774210    | 8.6 Mb      | II    | FISH        | paternal              | 12             |
|    | Gain       | 6p24.3       | rs6596796      | rs927402     | 7.7 Mb      | II    | FISH        | paternal              | 23             |

1, Affymetrix GeneChip Human Mapping 256K NspI; 2, Illumina's Sentrix HumanHap300 Genotyping Beadchip; n/a, parental DNA not available; 3, first aberrant probe; 4, last aberrant probe; 5, minimal size of aberration; 6, paternal inheritance can be concluded from the pedigree (see Fig. 3c)
### Table 5.1.2 Clinical characteristics of BPES-like patients with significant CNVs

| BPES features | 1 | 2 | 3* | 4 | 5 | 6 | 7 | 8 | 9 |
|---------------|---|---|----|---|---|---|---|---|---|
| Blepharophimosis | + | + | n/a | + | - | + | + | + | + |
| Ptosis | + | + | n/a | + | + | + | + | + | + |
| Epicantthus | + | + | n/a | - | - | + | + | + | - |
| inversus | - | + | n/a | + | - | - | + | + | - |
| Telecanthus | - | + | n/a | + | - | - | - | - | - |

**Additional features**

| Menstrual abnormalities | male | male | male | male | -, age? | -, 15y | +, 19y | -, 7y | -, 43y |
|-------------------------|------|------|------|------|---------|--------|--------|-------|--------|
| Psychomotor retardation | -    | +    | n/a  | -    | -       | -      | +      | +     | +      |
| Growth retardation      | -    | -    | n/a  | -    | -       | -      | +      | -     | -      |
| Microcephaly            | -    | -    | n/a  | -    | -       | -      | +      | +     | -      |
| Abnormal ears           | +    | +    | n/a  | -    | +       | -      | +      | +     | -      |
| Abnormal nose           | +    | +    | n/a  | -    | +       | -      | +      | -     | -      |
| Flattened and broad nose | +    | +    | n/a  | -    | -       | +      | +      | -     | +      |
| Skeletal anomaly        | -    | +    | n/a  | -    | -       | -      | -      | +     | -      |
| Syndactyly              | -    | -    | n/a  | -    | -       | -      | -      | +     | -      |
| Clinodactyly            | -    | -    | n/a  | -    | -       | -      | -      | +     | -      |
| Other                   | -    | -    | central and peripheral hypotonia, pectus excavatum, atrial septal defect type II | reduced iris pigmentation, mild Brushfield spots | - | midface hypoplasia, round face, narrow palate | brachycephaly, diastasis recti | - | - |

*n/a, not available; *, patient shows at least two characteristics of typical BPES and other features are unknown*
Figure 5.1.1 Case 2 (a) Deletion of chromosome 17q21.31 (485 kb) found with the Illumina’s Sentrix HumanHap300 Genotyping Beadchip. (b) MLPA analysis confirmed the deletion. Deleted probes: MAPT and KIAA1267. (c) Picture of the eyes of case 2, characterized by blepharophimosis, bilateral upper lid ptosis, epicanthus inversus and telecanthus.

responsible for the BPES-like features in patient 3.

In patient 4 we detected a novel rearrangement, being an interstitial deletion of chromosome 10p12.33p12.31 (4.5 Mb) (Fig. 5.1.2). It was shown to occur de novo and it is therefore likely to be causative. The clinical features of this patient include blepharophimosis, ptosis, epicanthal folds, ectropion of the lower eyelid, S-shaped upper eyelid, synophrys, high palate, broad hands and feet, and an atrial septal defect type II. This patient has a normal psychomotor development.

**Inherited single CNVs**

In patient 5 a small interstitial duplication of 545 kb on chromosome 11p15.4 was detected. This gain was not reported as a variant in the DGV, but was found in the phenotypically normal mother of this patient, probably suggesting absence of a causal relation between the duplication and the BPES-like phenotype in the child.

Furthermore, in case 6 an interstitial duplication of chromosome 9q34.1q34.2 (1.4 Mb) was found that was not described in the DGV. The mother of this patient was shown to carry the same duplication. The phenotype of patient 6 is characterized by bilateral ptosis, mild epicanthus inversus, horizontal nystagmus and high hypermetropia, while her mother displayed a mild ptosis and strabismus for which she underwent surgery. The occurrence of a phenotype in mother and child might suggest a causal relationship of the novel duplication and the phenotype.

**Complex CNVs**

In three cases more complex rearrangements were identified (cases 7, 8 and 9). In these patients both a duplication and a deletion were found on different chromosomes, suggesting the occurrence of an unbalanced translocation (Table 5.1.1).
Patient 7 was found to carry a terminal duplication of chromosome 10q (21.9 Mb) and a terminal deletion of chromosome 11q (5 Mb). Recently, a patient was described with approximately the same duplication of chromosome 10q and a deletion located on chromosome 4q (Bartholdi et al. 2008). This patient displayed the following clinical features: blepharophimosis, ptosis, epicanthus inversus, downslanting palpebral fissures, generalized hypotonia and developmental delay. The phenotype was ascribed to the duplication of chromosome 10q (Bartholdi et al. 2008). Our patient 7 showed a similar phenotype, therefore we hypothesize that the duplication of chromosome 10q might contribute to the BPES-like phenotype in this patient. For patient 7 it could not be confirmed whether this complex rearrangement arose from a balanced translocation in one of the parents.

Patient 8 showed a terminal duplication of chromosome 3q (4 Mb) and a terminal deletion of chromosome 13q (5 Mb). FISH analysis revealed the presence of an unbalanced translocation in the patient and showed no abnormalities in the parents. This patient showed a BPES-like phenotype and some additional dysmorphic features. In the ECARUCA database 28 cases were listed with a del(13)(q33.3q34). In 4/28 blepharophimosis was described as a clinical feature, in 3/28 ptosis, and in 2/28 telecanthus. No association between BPES-like features and 3q29 could be found in literature.
In patient 9 a terminal deletion of chromosome 3p (8.6 Mb) and a terminal duplication of chromosome 6p were observed (7.7 Mb) (Fig. 5.1.3a). Her facial appearance is characterized by blepharophimosis, ptosis, flattened and broad nose, long philtrum (IV-2) (Fig. 5.1.3d). In addition she displays psychomotor retardation. Patients with a terminal deletion of the short arm of chromosome 3 have been described to display blepharophimosis, epicanthus, upturned nose, long philtrum, microcephaly and polydactyly (Malmgren et al. 2007). Both the terminal deletion of 3p and terminal duplication 6p are associated with BPES-like features according to literature (Schinzel 2001). With standard G-banding the deletion and duplication were not visible. FISH with DNA probes specific for the subtelomeric region of chromosome 3p and 6p revealed that this rearrangement arose by an unbalanced translocation between chromosome 3p and 6p (Fig. 5.1.3b). Furthermore, another patient of this family with similar clinical features was found to have the same unbalanced rearrangement using SNP array analysis (III-5) (Fig. 5.1.3d). Subsequently, segregation analysis of the 3;6 translocation was performed in other members by FISH analysis (Fig. 5.1.3c), and revealed a familial 3;6 translocation. An unbalanced translocation, resulting in a terminal duplication of chromosome 3p and a terminal deletion of chromosome 6p, was observed in one family member (V-2). This patient showed no blepharophimosis, but displayed macrocephaly, Dandy-Walker malformation, hypoplasia of the cerebellum, hypertelorism, divergent strabismus, broad and flat nasal bridge and low set ears (Fig. 5.1.3d).

Previously performed conventional karyotyping revealed no chromosome abnormalities in patients 7, 8 and 9. These findings demonstrate that even large chromosomal imbalances are not always easily detected with standard G-banding, emphasizing the importance of a whole-genome screen with a high resolution array technique.

Candidate gene analysis
Assuming that the identified CNVs are causative for BPES-like phenotypes, it can be postulated that the corresponding chromosomal regions might reveal some relevant candidate genes contributing to some specific features. Most of these rearrangements, however, are too large to allow pinpointing of major candidate genes. Despite this, we used the software tool Anni in order to find functional associations between large numbers of genes contained in the identified CNVs and biomedical information from literature (Jelier et al. 2007). However, for all these regions no significant candidate genes were found. The availability of more BPES-like patients and more subtle rearrangements may be useful in the search for candidate genes involved in BPES-like phenotypes.

General conclusion
BPES-like features are associated with many syndromes and chromosomal disorders. In this study novel rearrangements were identified in 33% of patients with BPES-like phenotypes. These changes are presumed to contribute to the phenotype in most cases. Overall, we demonstrated that whole-genome high-density array screening is a powerful strategy to reveal the underlying genetic defect in BPES-like phenotypes. We conclude that patients with all 4 main features of typical BPES should be tested first for genetic defects in FOXL2. However, patients with a BPES-like phenotype that can be distinguished from typical BPES, should be tested with a genome wide array prior to
Figure 5.1.3 Case 9 (a) Terminal deletion of chromosome 3p25.3 (8.6 Mb) and terminal duplication of 6p24.3 (7.7 Mb) detected with the Illumina's Sentrix HumanHap300 Genotyping Beadchip. The derivative chromosome 3 was not observed by conventional G-banding. (b) FISH analysis revealed the presence of an unbalanced 3;6 translocation. Left panel, control probe: CEP3 (red) (Vysis), 6pter probe: GS-196I5 (green); right panel, control probe: CEP3 (red) (Vysis), 3pter probe; GS-186B18 (green). (c) Pedigree of the family with the segregating t(3;6) analyzed with FISH experiments. [ ] balanced t(3;6); [ ] 3p25.3 deletion and 6p24.3 duplication; [ ] 3p25.3 duplication and 6p24.3 deletion. (d) Facial picture of case 9 (IV-2), characterized by blepharophimosis, ptosis, flattened and broad nose. Facial pictures of two relatives (III-5, IV-13) with the same unbalanced translocation as case 9 are presented. These members show similar clinical features. In addition, a facial picture of a relative (V-2) with the opposite unbalanced translocation is shown. No BPES-like features are seen in this child.
**FOXL2 genetic testing.**

**Acknowledgements**

We are grateful to the patients and their families. We also want to thank the technicians of the Laboratory of Diagnostic Genome Analysis, Leiden University Medical Centre for performing conventional karyotyping and FISH experiments. This study was supported by the following grants: Specialisatiebeurs from IWT (to B.D.); K.A.N. 1.5.244.05 from the Research Foundation - Flanders (FWO-Vlaanderen) (to E.D.B.).

This research followed the tenets of the Declaration of Helsinki.

**References**

Bartholdi D, Toelle SP, Steiner B, Boltshauser E, Schinzel A, Riegel M. 2008. Blepharophimosis and mental retardation (BMR) phenotypes caused by chromosomal rearrangements: Description in a boy with partial trisomy 10q and monosomy 4q and review of the literature. Eur J Med Genet 51:113-123.

Beysen D, Raes J, Leroy BP, Lu cassen A, Yates JR, Clayton-Smith J, Ilyina H, Brooks SS, Christin-Maire S, Fellous M, Fryns JP, Kim JR, Lapunzina P, Lemyre E, Meire F, Messiaen LM, Oley C, Splitt M, Thom son J, Van de Peer Y, Veitia RA, De Paepe A, De Baere E. 2005. Deletions involving long-range conserved nongenic sequences upstream and downstream of FOXL2 as a novel disease-causing mechanism in blepharophimosis syndrome. Am J Hum Genet 77:205-218.

Beysen D, De Paepe A, De Baere E. 2009. FOXL2 mutations and genomic rearrangements in BPES. Hum Mut 30:158-169.

Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, Bisceglia L, Zelante L, Nagaraja R, Porcu S, Serafina Ristaldi M, Marzella R, Rocchi M, Nicolino M, Lienhardt-Roussie A, Nivelon A, Verloes A, Schlessinger D, Gasparini P, Bonneau D, Cao A, Pilota G. 2001. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 27:159-166.

Dauwerse JG, Kievits T, Beverstock GC, van der Keur D, Smit E, Wessels HW, Hagemeijer A, Pearson PL, van Ommen GJ, Breuning MH. 1990. Rapid detection of chromosome 16 inversion in acute nonlymphocytic leukemia, subtype M4: regional localization of the breakpoint in 16p. Cytogenet Cell Genet 53:126-128.

De Baere E, Dixon MJ, Small KW, Jabs EW, Leroy BP, Devriendt K, Gillerot Y, Meire F, Van Maldergem L, Courtens W, Hjalgrim H, Huang S, Liebaers I, Van Regemorter N, Touraine P, Prapanhajon V, Verloes A, Udar N, Yellore V, Chalukya M, Yelchits S, De Paepe A, Kuttenn F, Fellous M, Veitia R, Messiaen L. 2001. Spectrum of FOXL2 gene mutations in blepharophimosis/ptosis/epicanthus inversus syndrome (BPES) families demonstrates a genotype–phenotype correlation. Hum Mol Genet 10:1591-1600.

De Baere E, Beysen D, Oley C, Lorenz B, Coquet J, De Sutter P, Devriendt K, Dixon M, Fellous M, Fryns JP, Garza A, Jonsrud C, Koivisto PA, Krause A, Leroy BP, Meire F, Plomp A, Van Maldergem L, De Paepe A, Veitia R, Messiaen L. 2003. FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am J Hum Genet 72:478-487.

Guercio JR, Martyn LJ. 2007. Congenital malformations of the eye and orbit. Otolaryngol Clin North Am 40:113-140.

Jelir R, Jenster G, Dorssers LC, Wouters BJ, Hendriksen PJ, Mons B, Delwel R, Kors JA. 2007. Text-derived concept profiles support assessment of DNA microarray data for acute myeloid leukemia and for androgen receptor stimulation. BMC Bioinformatics 18:8-14.

Koolen DA, Vissers LE, Pfundt R, de Leeuw N, Knijft SG, Regan R, Kooy RF, Reyniers E, Romano C, Fichera M, Schinzel A, Baumer A, Anderlid BM, Schoumans J, Knoers NV, van Kessel AG, Siermans EA, Veltman JA, Brunner HG, de Vries BB. 2006. A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. Nat Genet 38:999-1001.

Koolen DA, Sharp AJ, Hurst JA, Firth HV, Knight SJ, Goldenberg A, Saugier-Veber P, Pfundt R, Vissers LE, Destree A, Grisard B, Rooms L, Van der Aa N, Field M, Hackett A, Bell K, Nowaczyk MJ, Mancini GM, Poddighe P, Schwartz CE, Rossi E, De Gregori M, Antonacci-Fulton LL, McLellan MD, Garrett JM, Wiechert MA, Miner TL, Crossby S, Ciccone R, Willatt L, Rauch A, Zenker M, Aradhya S, Manning MA, Strom TM, Wagenstaller J, Krepsisci-Santos AC, Vianna-Morgante AM, Rosenberg C, Price SM, Stewart H, Shaw-Smith C, Brunner HG, Wilkie AO, Veltman JA, Zuffardi O, Eichler EE, de Vries BB. 2008. Clinical and molecular delineation of the 17q21.31 microdeletion syndrome. J Med Genet 45:710-720.

Laccone F, Hannibal M, Neeser J, Grisold W, Chance P, Rehder H. 2008. Dysmorphic syndrome of hereditary
neuralgic amyotrophy associated with a SEPT9 gene mutation - a family study. Clin Genet 74:279-283.
Li C, Wong WH. 2001. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci 98:31-36.
Malmgren H, Sahlén S, Wide K, Lundvall M, Blennow E. 2007. Distal 3p deletion syndrome: detailed molecular cytogenetic and clinical characterization of three small deletions and review. Am J Med Genet A 143:2143-2149.
de Ravel T, Aerssens P, Vermeesch JR, Fryns JP. 2005. Trisomy of chromosome 16p13.3 due to an unbalanced insertional translocation into chromosome 22p13. Eur J Med Genet 48:355-359.
Schinzel A, Binkert F, Lillington DM, Sands M, Stocks RJ, Lindenbaum RH, Matthews H, Sheridan H. 1991. Interstitial deletion of the long arm of chromosome 18, del(18)(q12.2q21.1): a report of three cases of an autosomal deletion with a mild phenotype. J Med Genet 28:352-355.
Schinzel A. 2001. Catalogue of Unbalanced Chromosome Aberrations in Man, 2nd Edition, Walter de Gruyter, Berlin New York.
Shaw-Smith C, Pittman AM, Willatt L, Martin H, Rickman L, Gribble S, Curley R, Cumming S, Dunn C, Kalaitzopoulos D, Porter K, Prigmore E, Krepischi-Santos AC, Varela MC, Koiffmann CP, Lees AJ, Rosenberg C, Firth HV, de Silva R, Carter NP. 2006. Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet 38:1032-1037.
Slavotinek AM. 2008. Novel microdeletion syndromes detected by chromosome microarrays. Hum Genet 124:1–17.
Stankiewicz P, Beaudet AL. 2007. Use of array CGH in the evaluation of dysmorphology, malformations, developmental delay, and idiopathic mental retardation. Curr Opin Genet Dev 17:182–192.
Thienpont B, Breckpot J, Holvoet M, Vermeesch JR, Devriendt K. 2007. A microduplication of CBP in a patient with mental retardation and a congenital heart defect. Am J Med Genet A 143:2160-2164.
Tinkle BT, Christianson CA, Schorry EK, Webb T, Hopkin RJ. 2003. Long-term survival in a patient with del(18)(q12.2q21.1). Am J Med Genet A 119:66-70.
Wagenstaller J, Spranger S, Lorenz-Depiereux B, Kazmierczak B, Nathrath M, Wahl D, Heye B, Glaser D, Liebscher V, Meitinger T, Strom TM. 2007. Copy-number variations measured by single-nucleotide-polymorphism oligonucleotide arrays in patients with mental retardation. Am J Hum Genet 81:768-779.
White SJ, Vink GR, Kriek M, Wuyts W, Schouten J, Bakker B, Breuning MH, den Dunnen JT. 2004. Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. Hum Mutat 24:86-92.
Winter R, Baraitser M. 2008. London Medical Databases, edition 1.0.13, London.
Zlotogora J, Sagi M, Cohen T. 1983. The blepharophimosis, ptosis, and epicanthus inversus syndrome: delineation of two types. Am J Hum Genet 35:1020-1027.